In this study, the hypothesis that a subset of granulocyte colony-stimulating factor (G-CSF)-mobilized CD34 + blood cells may actively induce an allogeneic T cell response in vitro was tested. Circulating CD34 + cells were purified to у98% by high gradient magnetic separation and then analyzed for the coexpression of HLA-DR, the common ␤-chain of the leukointegrin family CD18 and costimulatory molecules CD80 (B7-1) and CD86 (B7-2). These antigens were expressed on average on: 94.9 ؎ 2.5%, 64.4 ؎ 15.4%, 0% and 1. 
Summary:
In this study, the hypothesis that a subset of granulocyte colony-stimulating factor (G-CSF)-mobilized CD34 + blood cells may actively induce an allogeneic T cell response in vitro was tested. Circulating CD34 + cells were purified to у98% by high gradient magnetic separation and then analyzed for the coexpression of HLA-DR, the common ␤-chain of the leukointegrin family CD18 and costimulatory molecules CD80 (B7-1) and CD86 (B7-2). These antigens were expressed on average on: 94.9 ؎ 2.5%, 64. 4 Circulating hematopoietic stem cells, which are characterized by the expression of the CD34 antigen, can be significantly increased by mobilization from bone marrow with chemotherapy and/or growth factors, such as granulocytemacrophage colony-stimulating factor (GM-CSF) or granulocyte colony-stimulating factor G-CSF. [1] [2] [3] Autologous and allogeneic transplantation with highly enriched CD34 + cells results in a complete hematopoietic engraftment in patients who have received myeloablative chemo-radiotherapy, and the absolute number of CD34 + progenitor cells in the graft is crucial for a rapid hematological recovery. [4] [5] [6] [7] [8] A major problem related to the use of mobilized peripheral blood stem cells (PBSC) for allogeneic transplantation has been the content of CD3 + T cells in the leukapheresis product which is significantly higher than in the unstimulated marrow mononuclear fraction, potentially increasing the risk of acute and/or chronic graft-versus-host disease (GVHD). Thus, it has been hypothesized that a highly enriched CD34
+ T cell-depleted cell population may better engraft allogeneic receipients without GVHD. In addition, previous experiments in mice demonstrated that allogeneic resistance can be overcome by increasing the number of stem cells in the graft. 9 These experimental findings prompted clinical studies in humans where transplantation of a large number of selected CD34 + cells, collected from marrow and blood upon G-CSF mobilization from haploidentical 'three loci' mismatched donors, achieved engraftment in the majority of patients. 10 Selection of CD34 + cells may also be considered as a useful means of depleting professional antigen presenting cells (APCs), in particular dendritic cells, which might induce graft rejection by presenting very efficiently donor hystocompatibility antigens to host T cells.
Recently, we demonstrated that CD34 + /CD18 + marrow cells include a B7-2 (CD86)-positive cell subset that can efficiently present alloantigen to T cells from HLA-incom-patible donors. 11 A previous report showed that exposure to G-CSF has a protective effect on BM progenitor cells from T cell cytotoxic activity in vitro. 12 In this study we investigated the expression of accessory molecules and the alloantigen presenting function of normal CD34
+ blood cells after in vivo priming with G-CSF. These cells elicited a response of allogeneic CD4 + or CD8 + T cells in primary MLC. Furthermore, consistent with previous results in marrow, we showed that G-CSF-mobilized CD34 + /CD18 Ϫ blood cells are poorly immunogenic. The role of B7 costimulatory molecules in the immunogenic activity of CD34 + blood cells was investigated and the constitutive expression of CD86 was detected in a smaller fraction of blood CD34
+ cells than marrow CD34 + cells. 11 However, we documented the upregulation of CD80 and CD86 on CD34 + /CD18 + cells upon encountering autologous or allogeneic T cells in vitro. Also, preincubation with anti-CD80 and anti-CD86 antibodies greatly reduced the in vitro allogeneic T cell response. These findings suggest that selection of CD34
+ progenitors, devoid of cells with the potential for expression of B7 molecules, might help clinical investigators in designing new protocols for transplantation of allogeneic hematopoietic stem cells.
Materials and methods

Monoclonal antibodies (mAbs)
Human mAbs used in this study are as follows: HPCA-2 (anti-CD34, IgG1) fluorescein isthyocianate (FITC), phycoerythrin (PE) or peridin chlorophyll protein (PerCP) conjugated, HLA-DR PE (IgG2a), CD18 FITC (IgG1), B7-1 PE (anti-CD80, IgG1), CD4 FITC (IgG1) and CD8 PE (IgG1) from Becton Dickinson (San Jose, CA, USA); B7-2 PE (IgG2b) or FITC (IgG1) (anti-CD86) from PharMingen (San Diego, CA, USA). Isotype controls IgG1 FITC or PE or PerCP and IgG2a PE are from Becton Dickinson and IgG2bPE is from PharMingen.
Cell separation
Blood and apheresis samples were obtained with informed consent from adult normal healthy donors. PBSC donors were treated with 10 g/kg/day s.c. of glycosylated G-CSF (Lenograstin; Rhone-Poulenc Rorer, Milan,Italy) for 5-6 days and stem cell collection was begun on day 5. All samples were separated by centrifugation over FycollHypaque (Nycomed Pharma, Oslo, Norway) gradients to obtain mononuclear cells. Light density cells were washed twice in phosphate buffer saline (PBS) with 1% bovine serum albumin (BSA; Sigma Chemical Co, St Louis, MO, USA), and CD34 + cells were highly purified by MiniMACS high gradient magnetic separation column (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. 13 To assess the purity of the CD34 + and CD8 + T cells by a two-step procedure including a depletion of adherent cells by 1-4 h adherence to plastic on tissue culture flasks at 37°C, followed by purification of the T cell subsets by high gradient magnetic separation (MiniMACS). 13 Aliquots of separated lymphocytes were stained with anti-CD4 FITC or anti-CD8 PE, or appropriate isotype controls mAbs and then analyzed on a FACScan (Becton Dickinson) to determine the purity achieved.
Primary MLC
Unfractionated apheresis mononuclear cells, isolated CD34
+
, CD34
+ /CD18 + and CD34 + /CD18 Ϫ cells, as well as autologous and third party blood mononuclear control cells were irradiated (3000 cGy) and tested as stimulators in primary MLC. Cells were resuspended in medium containing RPMI-1640, 25 mm Hepes, 1 U/ml penicillin, 1 g/ml streptomycin and 15% AB human serum (HS) that had been inactivated at 56°C for 30 min. 5 ϫ 10 4 purified CD4 + or CD8 + T cells were mixed with six dilutions of stimulators, at 1:1 to 1:32 ratio, in round-bottomed 96-well plates for 6 days at 37°C in a 5% CO 2 humidified atmosphere. Cells were pulsed with 1 Ci /well 
In blocking experiments irradiated CD34
+ blood cells and allogeneic mononuclear cells, or in selected experiments CD4 + T cell responders, were separately incubated with blocking anti-CD86 (FUN-1 or IT2.2) (PharMingen) and/or anti-CD80 (L307.2) (Becton Dickinson) mAbs, 14 or specific irrelevant isotype control mAbs, at the concentration of 10 g/10 6 cells in 10% FCS RPMI, or with medium alone, for 30 min at room temperature. Then the cells were washed and mixed in primary MLC at 1:2 ratio (stimulators: 2.5 ϫ 10 4 vs responders: 5 ϫ 10 4 ).
Limiting dilution assay (LDA)
Purified stimulator cells were suspended in medium, irradiated (3000 cGy), and dispensed in 24 replicates at 500, 250, 125, 63, 32, 16 and eight cells per well in Vbottomed plates with responding nylon wool-purified T lymphocytes from HLA-DR incompatible healthy volunteers, as previously described. 11 Responders were plated at 1 ϫ 10 4 cells per well with stimulator cells or with medium alone. Cultures were maintained in a humidified atmosphere at 37°C and 5% CO 2 . Cells were pulsed with 1 Ci/well 3 H-thymidine for 18 h before harvest on day 6 to measure proliferation. Wells were considered positive if counts per minute (c.p.m.) were greater than the mean plus three standard deviations over the negative control given by responder cells cultured in medium. The frequency of MLC stimulating cells was calculated according to Taswell 15 as the reciprocal of the number of stimulator cells resulting in 37% nonresponding wells. The 2 minimization method was used to assess the probability that data fit to a Poisson model as described.
Kinetic expression of B7-1 (CD80) and B7-2 (CD86) molecules on CD34
+ blood cells 
CFU-C and LTC-IC assays
Purified CD34
+ cell subsets were evaluated for colony-forming cells (CFU-C) in semisolid medium as previously described. 16 To measure the optimum clonogenic efficiency (CE), 10% (v/v) of a selected lot of phytohemagglutinin lymphocyte-conditioned medium (PHA-LCM) was added and the final concentration of methylcellulose was 1.1%. Granulocyte-macrophage CFU (CFU-GM), erythroid progenitors (burst-forming unit erythroid, BFU-E) and mixed colonies (CFU granulocyte, erythroid, monocyte, megakaryocyte (CFU-GEMM) ) were scored after 14 days of incubation at 37°C in a fully humidified 5% CO 2 atmosphere. Also, purified CD34 + /CD18 Ϫ blood cells were plated in long-term cultures as previously described. 16 After 5 weeks in culture the cells were then evaluated for their secondary CFU-C activity and the number of long-term culture-initiating cells (LTC-IC) was calculated as previously reported. 16 
Results
CD4
+ and CD8
cell proliferative response to allogeneic G-CSF-mobilized CD34
+ blood cells
The ability of G-CSF-mobilized CD34 + cells to stimulate an in vitro allogeneic T cell response was first investigated. CD34
+ blood cells were purified to Ͼ98% by high gradient magnetic separation and were found 94.9 Ϯ 2.5% HLA-DR + by two-color flow cytometry analysis (data not shown). CD4
+ and CD8 + T cells were purified to Ͼ95% by plastic adherence to remove monocytes, followed by high gradient magnetic separation. CD34
+ blood cells, unfractionated PBSC, autologous and third party blood mononuclear cells were irradiated (3000 cGy) and incubated in MLC for 6 days with allogeneic HLA-DR incompatible T cell proliferative response and were comparable to third party blood mononuclear cells, whereas PBSC showed an average three-fold lower allostimulatory activity than CD34 + cells (Figure 1a) . Furthermore, CD34 + cells also induced a CD8 + T cell proliferative response in the absence of CD4
+ T helper cells. In contrast, both third party and apheresis mononuclear cells were less effective than CD34 + cells, and in particular apheresis mononuclear cells were 8 to 10-fold less efficient than CD34
+ blood cells in stimulating CD8
+ T cell proliferation (Figure 1b) . Also, CD34 + cells were shown to present alloantigen since they induced a 10-fold greater response of allogeneic rather than autologous T cells (data not shown).
Limiting dilution analysis (LDA) of CD34
+ cell antigen presenting function mal HLA-DR incompatible volunteers. Data obtained from CD34 + cells consistently fit single hit kinetics, in contrast to data from PBSC that showed a complex pattern, consistent with the presence of a cell with a T lymphocyte suppressing activity becoming evident in cultures containing an increasing concentration of stimulator cells per well. Three experiments produced similar results and a representative example is shown in Figure 2 . Results of LDA experiments confirmed the findings in bulk MLC, and showed a higher frequency of allostimulating cells among CD34
+ purified blood cells than among PBSC.
Expression of CD18 on G-CSF-mobilized CD34
+ hematopoietic progenitors
We previously observed that an average of 25% CD34 11 Therefore, the expression of CD18 was also investigated on CD34
+ blood cells from G-CSF-treated donors. G-CSF-mobilized CD34 + blood cells were isolated from apheresis samples from normal adult donors, as described above, and were then studied by cytofluorimetry. After staining with a CD18 mAb, an average of 35.6 Ϯ 15.4% CD34 + blood cells appeared below a threshold set on the upper limit of fluorescence of cells stained with irrelevant matched isotype control (n = 14 experiments) (data not shown). The kinetics of G-CSFmediated mobilization of CD34 + /CD18 Ϫ cells into the blood were evaluated in three PBSC healthy donors and showed the same pattern as the whole CD34
+ cell population with a peak occurring on day 5. Thus, to investigate their immunogenic function, CD34 + /CD18 + and CD34
+
/CD18
Ϫ cell populations were purified to Ͼ98% degree by a two-step procedure including a high gradient separation of CD34 + cells followed by a fluorescence activated cell sorting. Immunomagnetically isolated CD34 + cells were sorted into CD18 + and CD18 Ϫ fractions using windows that allowed no overlap at reanalysis on a FACScan.
CFU-C and LTC-IC in G-CSF-mobilized CD34
+ /CD18
Ϫ blood cells
According to previous findings, CD34 + /CD18 Ϫ marrow cells are highly enriched in early progenitors and relatively depleted in more mature CFU-C. 11, 17 To test whether G-CSF-mobilized CD34 + /CD18 Ϫ blood cells may also be potentially capable of engrafting, these cells were evaluated in short-and long-term culture assay. In four separate experiments the median clonogenic efficiency (CE) of CD34 + /CD18 Ϫ cells, which induced a poor allogeneic T cell response, even at the highest concentration tested (2.5 ϫ 10 4 cells per well at a 1:2 stimulator:responder ratio) (n = 3 experiments) ( Figure 3) .
Kinetics of B7-1 (CD80) and B7-2 (CD86) expression on CD34
+ blood cells T cell proliferation requires the antigen receptor triggering followed by a second signal from antigen presenting cells (APC). CD80 and CD86 are homologous molecules expressed on the cell surface of APCs, and can be upregulated upon T cell interaction. 18 Also, each of them can upregulate T cell function upon binding to CD28, or downregulate T cell function upon binding to CTLA-4.
14, [18] [19] [20] In this set of experiments, we evaluated the expression of 
CD80 and CD86 on G-CSF-mobilized CD34
+ blood cells before and after culture for 24-30 h, or with autologous or allogeneic responders (Figure 4 ). Immediately after isolation, CD34
+ blood cells were negative for CD80 and on average 1.9 Ϯ 1.2% were weakly positive for CD86 (n = 9 experiments). This pattern of expression of CD80 and CD86 was also observed after 24-30 h of culture in medium alone. Moreover, when CD34
+ blood cells were tested in MLC with either autologous or allogeneic mononuclear cells, or in selected experiments with purified CD4 + or CD8
+ T cells, on average 10.7 Ϯ 2.6% CD34 + blood cells were CD86 + (n = 8 experiments), and on average 6.9 Ϯ 4.9% were CD80 + (n = 6 experiments). Three-color cytofluorimetry also showed that the upregulation of CD86 after 24 h in MLC mainly occurred among CD34 + /CD18 + cells ( Figure 5 ). These data demonstrate that CD86 is expressed on a very small proportion of G-CSF-mobilized CD34 + blood cells. However, a subset of CD34 + cells can rapidly upregulate B7-1 and B7-2 molecules upon engagement with T cells.
Blocking effect of preincubation with anti-CD80 and anti-CD86 mAbs before primary MLC
Because upregulation of B7 molecules occurs on CD34 + blood cells upon engagement with T cells, we tested the hypothesis that blocking CD80 and CD86 receptors before initiating the MLC could reduce the immunogenic capacity of CD34 + cells. Preincubation with only anti-CD80 mAb or anti-CD86 mAb partially reduced the T cell response, as opposed to preincubation with specific isotype control mAbs. However, preincubation with anti-CD80 plus anti-CD86 mAbs resulted in a partial reduction of B7 positivestem cells after 30 h in MLC (data not shown), and induced on average 84 Ϯ 8% inhibition of T cell growth, as opposed to preincubation with control mAbs (n = 3 experiments) ( Figure 6 ). These data suggest that an initial signal through the B7:CD28 pathway may allow the upregulation of CD80 and CD86 on a subset of CD34 + blood cells. Also, it appears that on normal blood stem cells CD80 and CD86 molecules are additive in delivering costimulatory signals to allogeneic T cells.
Discussion
In this study, we demonstrate that a subset of normal G-CSF-mobilized CD34 + blood cells can efficiently present antigens and stimulate allogeneic CD4 + and CD8 + T cells in primary MLC. We also show that in vivo treatment with G-CSF does not modify the proportion and the function of CD18 Ϫ hematopoietic progenitors. This latter represents an enriched marrow and peripheral blood stem cell subset devoid of APCs and poorly stimulating allogeneic T cells in vitro. In fact, APC progenitors constitutively express CD18 and can upregulate B7 molecules upon T cell interaction. Thus, induction of these molecules on CD34
+ cells is probably responsible for initiating an allogeneic T cell response. We recently demonstrated that normal human CD34 + /CD18 + marrow cells include a CD86 + cell subset with potent APC capacity. 11 However, it has also been suggested that in vitro priming with G-CSF could protect marrow mononuclear cells from cytotoxic T cells. 12 In the present study we initially addressed the hypothesis that G-CSF-mobilized CD34 + blood cells still contain an immunogenic cell fraction. Bulk MLC experiments showed separate responses of CD4 + and CD8 + T cells to allogeneic CD34 MLC experiments also showed a consistently lower allogeneic T cell response to PBSC than to G-CSF-mobilized CD34 + blood cells. This was even more evident when the stimulating activity of CD34 + cells and PBSC was evaluated on a per cell basis. In fact, since increasing concentrations of PBSC reduced the T cell response, it could be hypothesized that a suppressing cell/factor might be present among G-CSF-mobilized blood mononuclear cells. Also, the allostimulating activity of blood cells from normal donors needs to be tested before and after receiving G-CSF against the same responders, to demonstrate whether the reduced APC activity of PBSC may be due to priming in vivo with G-CSF and/or to apheresis collection.
In unstimulated marrow CD34 + /CD18 Ϫ cells are enriched in early progenitors and stimulate poorly incompatible T cells both in bulk and LDA primary MLC. 11 Torensma et al 21 proposed that lack of negative regulator signals from the stroma may upregulate LFA-1 (CD18/CD11a) on a fraction of early CD34 + marrow cells, without decreasing their stem cell activity, within 24 h of liquid culture. In addition, we recently demonstrated that G-CSF modifies the phenotype and the cycling status of normal CD34 + cells. 21 Thus, the possibility that G-CSF-mediated stem cell mobilization may change the number and the function of CD34 + /CD18 Ϫ cells was tested. After G-CSF administration in normal PBSC donors the kinetics of mobilization of CD34 + /CD18 Ϫ blood cells was similar to CD34 + cells with a peak on day +5 of treatment. Flow cytometry experiments showed that CD18 and HLA-DR expression were similar on CD34 + cells from the leukapheresis product and unstimulated marrow. Short-term clonogenic assays (CFU-C) and long-term cultures (LTC-IC) demonstrated that similarly to their marrow counterparts, 11, 17 Antigen presentation must be followed by delivery of costimulatory signals in order to obtain a T cell response. CD80 and CD86 costimulatory molecules on professional APCs can induce T cell proliferation upon binding to CD28 receptor, or, alternatively, they can downregulate the T cell response upon binding to CTLA-4 receptor, potentially driving T cells to death. [18] [19] [20] 22 In our previous paper we observed the expression of CD86 on an average of 6% of marrow CD34
+ progenitors, and a higher frequency of stimulating cells in CD34 + /CD86 + than in CD34 + /CD86 Ϫ marrow cells. 11 Thus, the expression and the functional role of B7 costimulatory molecules have been assessed in G-CSF-mobilized CD34 + blood cells. These cells do not express CD80 constitutively, while on average Ͻ2% express CD86 weakly. However, three-color cytofluorimetry showed an increased expression of both CD80 and CD86 on a subset of CD34 + cells after 30 h of autologous or allogeneic MLC, and also that the upregulation of CD86 occurs mainly on CD34 + /CD18 + blood cells. These data suggest that T cell interaction contributes to the expression of B7 receptors on a subset of committed CD34 + cells. It is not known whether a direct cell-contact and/or the release of soluble factors, such as TNF-␣, mediates the induction of costimulatory molecules on the surface of APC progenitors. Although B7 molecules are induced on purified CD34 The hypothesis that initial B7:CD28 crosslinking on T cells may be required for induction of B7 molecules on CD34 + cells and proliferation of allogeneic T cells was tested by blocking experiments. Preincubation of CD34 + stimulators and responders with anti-CD80 and anti-CD86 mAbs before initiating the MLC reduced the development of CD34 + /CD80 + /CD86 + cells after 30 h, and inhibited on average Ͼ80% T cell proliferation after 6 days. In contrast, preincubation of the cells with only anti-CD80 or anti-CD86 mAb only partially modified the allo-T cell proliferation. Thus, it is likely that the inhibitory effect on T cell growth may be due to an impaired capacity of irradiated CD34 + cells, previously incubated with anti-CD80 and anti-CD86 mAbs, to deliver costimulatory signals through B7 molecules after HLA:T cell receptor binding. All these data indicate that on CD34
+ blood cells CD80 and CD86 molecules may play an important role in the initial activation of allogeneic CD4
+ or CD8 + T cells. Since CD8 + T cells can also be induced to cytotoxic T cells in the absence of exogenous help by dendritic cells, 23 or by B7-transfected P815 cells through the B7:CD28 pathway, 24 the hypothesis that CD34
+ /B7 + cells may stimulate not only the proliferation but also the lytic activity of CD8
+ T cells will be tested.
Expression of CD80 and CD86 has been observed on professional APCs, and also on a fraction of hematopoietic marrow and blood stem cells; thus, it is likely that CD34 + /CD18 + /CD86 + cells are progenitors committed to the monocyte/macrophage or dendritic lineage. It is not known whether a subset of CD34 + myeloid precursors can be induced to differentiate into APC by an interaction with alloantigens.
Selection of CD34 + /CD18 Ϫ cells from G-CSF-mobilized PBSC may result in the depletion of the CD34 + allostimulating cells. Thus, the possibility of isolating a great number of these progenitors from leukaphereses might be helpful in designing new strategies in allogeneic transplant, aimed at reducing graft rejection and at overcoming T cell response to HLA barriers. Alternatively, the complete blockade of B7 receptors on CD34 + stem cells might induce a T cell unresponsiveness 25 and prevent T cell alloreactivity in allogeneic transplants with purified CD34 + cells.
